Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 4/20 | 0.49 |
| ▸ | AKT2 | P31751 | 2/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.49 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797556 | 0.93 | MC4R (0.49) | MC4RAKT1AKT2AKT3AKT1S1 | |
| SCHEMBL4510471 | 0.83 | MC4R (0.56) | MC4RKMT2AMAPK1HRH2HRH1 | |
| SCHEMBL6017282 | 0.83 | AKT1 (0.67) | MC4RAKT1AKT2AKT3AKT1S1 | |
| SCHEMBL13229957 | 0.81 | AKT1 (0.72) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL2798976 | 0.80 | AKT1 (0.69) | MC4RAKT1AKT2AKT3AKT1S1 | |
| Hydrochloric Acid SCHEMBL6017793 | 0.80 | AKT1 (0.71) | AKT1AKT2AKT3AKT1S1 | |
| Hydrochloric Acid SCHEMBL2798045 | 0.80 | AKT1 (0.71) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL2798581 | 0.80 | MC4R (0.49) | MC4RAKT1AKT2AKT3AKT1S1 | |
| SCHEMBL2800450 | 0.80 | MC4R (0.48) | MC4RAKT1AKT2AKT3AKT1S1 | |
| SCHEMBL15810045 | 0.80 | HRH2 (0.58) | MC4RKMT2AMAPK1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MC4R 4675/4885AKT1 1/4885AKT2 2/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MC4R 4675/4885AKT1 1/4885AKT2 2/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MC4R 4675/4885AKT1 1/4885AKT2 2/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | MC4R 3848/4885AKT1 25/4885AKT2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.